Teva Pharmaceutical Industries (TEVA) Prepaid Assets (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Prepaid Assets came in at $1.0 billion in Q2 2026, down 4.61% on a YoY basis from $1.1 billion in Q2 2025, and down 3.36% quarter-over-quarter from $1.1 billion in Q1 2026.
Analysis
Teva Pharmaceutical Industries (TEVA) Prepaid Assets (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has reported Prepaid Assets for 14 consecutive years, with $1.0 billion the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Prepaid Assets fell 4.61% year-over-year to $1.0 billion; the trailing twelve-month figure through Jun 2026 stood at $1.0 billion (down 4.61% YoY), and the FY2025 full-year result was $1.1 billion, up 11.53% from the prior year.
- Prepaid Assets slipped to $1.0 billion in Q2 2026 per TEVA's latest filing, from $1.1 billion in the prior quarter.
- Across five years, Prepaid Assets topped out at $1.3 billion in Q1 2024 and bottomed at $1.0 billion in Q4 2024.
- Historically, Prepaid Assets has averaged $1.1 billion across 5 years, with a median of $1.1 billion in 2024.
- The sharpest annual moves came in 2023 and 2025: Prepaid Assets grew 17.76% in 2023, then dropped 23.8% in 2025.
- Over 5 years, Prepaid Assets stood at $1.2 billion in 2022, then rose by 8.0% to $1.3 billion in 2023, then declined by 19.84% to $1.0 billion in 2024, then gained by 11.53% to $1.1 billion in 2025, then declined by 7.84% to $1.0 billion in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $1.0 billion, $1.1 billion, and $1.1 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.56 Bn | 38.90 Bn | 2.15 Bn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn |
| 3 | Dr Reddys Laboratories | 9.86 Bn | 9.69 Bn | 396.53 Mn |
| 4 | Amneal Pharmaceuticals | 5.46 Bn | 5.33 Bn | 334.51 Mn |
| 5 | Bausch Health Companies | 2.37 Bn | 528.25 Mn | 2.10 Bn |
| 6 | Alvotech | 1.51 Bn | 1.37 Bn | 2.56 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn |
| 8 | Amphastar Pharmaceuticals | 992.90 Mn | 702.78 Mn | 93.47 Mn |
| 9 | Fennec Pharmaceuticals | 411.43 Mn | 370.18 Mn | 17.15 Mn |
| 10 | RedHill Biopharma | 181.39 Mn | 181.39 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.03 Bn |
| Mar 31, 2026 | 1.07 Bn |
| Dec 31, 2025 | 1.12 Bn |
| Sep 30, 2025 | 1.12 Bn |
| Jun 30, 2025 | 1.08 Bn |
| Mar 31, 2025 | 1.02 Bn |
| Dec 31, 2024 | 1.01 Bn |
| Sep 30, 2024 | 1.13 Bn |
| Jun 30, 2024 | 1.10 Bn |
| Mar 31, 2024 | 1.34 Bn |
| Dec 31, 2023 | 1.26 Bn |
| Sep 30, 2023 | 1.17 Bn |
| Jun 30, 2023 | 1.23 Bn |
| Mar 31, 2023 | 1.25 Bn |
| Dec 31, 2022 | 1.16 Bn |
| Sep 30, 2022 | 1.05 Bn |
| Jun 30, 2022 | 1.05 Bn |
| Mar 31, 2022 | 1.06 Bn |
| Dec 31, 2021 | 1.08 Bn |
| Sep 30, 2021 | 1.07 Bn |